Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Harrison SA, et al. Among authors: alpenidze d. Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9. Epub 2022 Jun 20. Nat Med. 2022. PMID: 35725922 Free PMC article. Clinical Trial.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group. Russell-Jones D, et al. Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210563 Free PMC article. Clinical Trial.
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.
Drai RV, Mayorov AY, Karonova TL, Parfenova TM, Makarenko IE, Magruk MA, Alpenidze DN, Kovalik VV, Zinnatulina BR, Grigorjeva IV, Andreeva AT. Drai RV, et al. Among authors: alpenidze dn. J Comp Eff Res. 2022 Dec;11(18):1337-1347. doi: 10.2217/cer-2021-0232. Epub 2022 Dec 13. J Comp Eff Res. 2022. PMID: 36511777 Free article. Clinical Trial.
Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine.
Rabdano S, Ruzanova E, Makarov D, Vertyachikh A, Teplykh V, Rudakov G, Pletyukhina I, Saveliev N, Zakharov K, Alpenidze D, Vasilyuk V, Arakelov S, Skvortsova V. Rabdano S, et al. Among authors: alpenidze d. Vaccines (Basel). 2024 Jan 19;12(1):100. doi: 10.3390/vaccines12010100. Vaccines (Basel). 2024. PMID: 38276672 Free PMC article.
17 results